Sumit Aggarwal - 16 Oct 2024 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
PRESIDENT AND CEO, Director
Signature
/s/ Sumit Aggarwal
Issuer symbol
N/A
Transactions as of
16 Oct 2024
Net transactions value
$0
Form type
4
Filing time
17 Oct 2024, 16:01:12 UTC
Previous filing
26 Jan 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELOX Common Stock Award $0 +165,000 +3347% $0.000000 169,930 16 Oct 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock award was made under the Issuer's 2018 Equity Incentive Plan and vests as to 25% on October 16, 2025 and in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein reflect the reverse stock split.